The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC).
William Nassib William
Research Funding - Astellas Pharma; Lilly
Heidi S. Erickson
No relevant relationships to disclose
Caimiao Wei
No relevant relationships to disclose
Nana Hanson
No relevant relationships to disclose
Ximing Tang
No relevant relationships to disclose
Jaime Rodriguez
No relevant relationships to disclose
Neda Kalhor
No relevant relationships to disclose
J. Jack Lee
No relevant relationships to disclose
Waun Ki Hong
No relevant relationships to disclose
Edward S. Kim
No relevant relationships to disclose
Ignacio Ivan Wistuba
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Pfizer
Research Funding - AstraZeneca; Bayer; Genentech; Merck; Myriad Genetics